Fortrea HoldingsFTRE
About: Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Employees: 15,500
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
40% more call options, than puts
Call options by funds: $29.1M | Put options by funds: $20.8M
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
0% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 64
3% less funds holding
Funds holding: 348 [Q3] → 337 (-11) [Q4]
3.23% less ownership
Funds ownership: 109.42% [Q3] → 106.19% (-3.23%) [Q4]
9% less capital invested
Capital invested by funds: $1.96B [Q3] → $1.78B (-$183M) [Q4]
35% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 126
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Citigroup Patrick Donnelly 33% 1-year accuracy 10 / 30 met price target | 55%upside $23 | Neutral Downgraded | 11 Dec 2024 |
Baird Eric Coldwell 42% 1-year accuracy 13 / 31 met price target | 68%upside $25 | Neutral Downgraded | 6 Dec 2024 |
Financial journalist opinion
Based on 10 articles about FTRE published over the past 30 days
